Niclas Stiernholm

YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada.

Trillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. It offers clinical programs, TTI-621 and TTI-622, target CD47, a signal that cancer cells frequently use to evade the immune system. The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada.

Trillium Therapeutics Inc. (TTI), is a biopharmaceutical company specializing in the development of innovative therapies for the treatment of immune-mediated disorders. The Company's therapeutic approaches are aimed at restoring balance to the immune system in conditions associated with aberrant or harmful immune responses, such as autoimmune disease, inflammatory disorders, and cancer. TTI's objective is to create a broad and innovative pipeline of proprietary biologic product opportunities, as part of its overall strategy of building and solidifying its reputation as a premier R & D company. The company's business model is to identify therapeutic candidates that have shown promise in animal models and to rapidly advance these into clinical testing. TTI is concentrating its efforts on preclinical and early clinical drug development, with the primary objective of demonstrating safety and proof-of-principle in man. The company has chosen to establish development partnerships for some of its projects at a preclinical stage, and anticipates advancing several others into clinical development on its own. TTI has five scientific programs at various stages of preclinical testing. Two of its programs focus on the immunoregulatory protein CD200 and its receptor, a third targets the activating Fc receptor Fc RIIa (CD32a) and the final two involve the use of a growth factor in the prevention of necrotizing enterocolitis and the treatment of interstitial cystitis.

Tarix Pharmaceuticals Ltd. develops peptide drugs. The private company is based in Brookline, MA. The company was founded by Joerg Gruber, Richard L. Franklin. Richard L. Franklin has been the CEO since incorporation.

Ontario Genomics Institute (Private Equity) is a Venture Capital firm in UK. The firm was founded in 2001. The firm is headquartered in London.

The Ontario Bioscience Industry Organization is a membership organization that engages in strategy, programming, policy development, and advocacy. The non-profit company is based in Toronto, Canada. The Canadian company was founded by Simon Goulet. Maura Campbell has been the CEO of the company since 2021.

Fight Against Cancer Innovation Trust is a venture capital firm founded in 2014. The firm is headquartered in Toronto, Canada.